Articles related to BUSINESS & POLICY

A cost-efficiency analysis found that ophthalmic ambulatory surgery centers may face growing financial pressure when performing procedures with high direct material costs under current Medicare reimbursement schedules.

ASHP urged HRSA in a June 2 letter to take immediate enforcement action against Eli Lilly after the manufacturer gave an initial group of 340B-covered entities five business days to submit detailed claims-level data or lose access to discounted pricing across its full drug portfolio, including in-house hospital pharmacy dispensing and medically administered products; as of mid-June, the threatened cutoffs had not yet taken effect for many affected entities.

The Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would authorize Medicare reimbursement for pharmacist-provided testing and treatment of flu, strep, RSV, and COVID-19 in states that already permit those services, cleared the House Committee on Ways and Means on May 21 with more than 110 congressional co-sponsors and support from over 170 organizations.

ACOG released its first maternal immunization schedule formally diverging from federal vaccine recommendations, following its February 2026 withdrawal from the CDC Advisory Committee on Immunization Practices over concerns about the committee’s scientific integrity.

Bausch + Lomb launched PreserVision AREDS3, a reformulation of its established AREDS2 supplement adding a proprietary B-vitamin complex, citing a narrative review of more than 20 human studies linking B-vitamin supplementation to reduced AMD risk.

US prescription drug expenditures reached $915.2 billion in 2025, with utilization growth rather than price increases accounting for the majority of the 12.7% rise, and clinic-sector spending projected to outpace hospital spending by a factor of three in 2026.